APA (7th ed.) Citation

Tadayoni, R., Sararols, L., Weissgerber, G., Verma, R., Clemens, A., & Holz, F. G. (2021). Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmologica (Basel), 244(2), 93. https://doi.org/10.1159/000513048

Chicago Style (17th ed.) Citation

Tadayoni, Ramin, Laura Sararols, Georges Weissgerber, Rohini Verma, Andreas Clemens, and Frank G. Holz. "Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration." Ophthalmologica (Basel) 244, no. 2 (2021): 93. https://doi.org/10.1159/000513048.

MLA (9th ed.) Citation

Tadayoni, Ramin, et al. "Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration." Ophthalmologica (Basel), vol. 244, no. 2, 2021, p. 93, https://doi.org/10.1159/000513048.